Blood clot is one of the serious complications in
the human body. When blood clots, major arteries or veins are blocked which
cease the normal blood flow. The cessation of normal blood flow can implicate
hemorrhage and often lead to heart attack and stroke. Thrombolytic therapy is a
treatment to dissolve solid blood clots by administrating thrombolytic drugs.
The length of the therapy depends upon the type or degree of complications. The
treatment may require almost one hour in the case of a heart attack or may need
48 hours in the case of deep vein thrombosis. Brain CT test, electrocardiogram,
and electroencephalogram are effective ways to evaluate whether patients are
good candidates for thrombolytic therapy. Patients who had undergone recent
surgery and blood thinning treatment or with conditions such as pregnancy,
trauma, and high blood pressure are not recommended to thrombolytic therapy.
Read Report Overview: https://www.transparencymarketresearch.com/thrombolytic-therapy-market.html
Urokinase, streptokinase, and tissue plasminogen
activator (tPA) are basic thrombolytic drugs available in the market for
thrombolytic therapy. In 1933, the efficiency of streptokinase as a
thrombolytic agent was first stated. Later on, streptokinase was applied to
acute myocardial infarction. Unlike streptokinase, urokinase has the ability to
catalyze fibrin formation from plasminogen. The growth of the global
thrombolytic therapy market is driven by several factors such as aging
population, awareness about the adverse effect of thrombosis, rate of diagnosis
and treatment, and increase in the incidence of hypertension, kidney diseases,
strokes, and other cardiovascular diseases. However, this market is likely to
witness hindrances such as strict drug regulatory system and high drug pricing,
which, in turn, might restrict the market growth. Nevertheless, new treatment
options and technological breakthroughs are anticipated to highlight new
avenues for the market growth in the near future.
Request a Sample of Thrombolytic
Therapy Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=37127
The global market for thrombolytic therapy has been
segmented based on drug type, application, distribution channel, and region. In
terms of drug type, the market is categorized into fibrin specific drugs and
non-fibrin specific drugs. The fibrin specific drugs segment is further
segmented into tissue plasminogen activator, reteplase, tenecteplase, and
others. The non-fibrin specific drugs segment is categorized into urokinase,
streptokinase, and plasminogen-activating complex.
Enquiry before Buying Thrombolytic
Therapy Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=37127
In terms of application, the global market is
classified into acute myocardial infarction, pulmonary embolism, deep vein
thrombosis, blocked catheters, acute ischemic strokes, and others. Most of the
drugs are administered intravenously, and the doses are recommended on the
basis of the patient’s medical history. In terms of distribution channel, the
market is segmented into hospital pharmacies, retail pharmacies, and
e-pharmacies. Increasing number of retail pharmacies, self-medication tendency,
and merging of hospital pharmacies are the factors to consider in this market.
The thrombolytic drugs are rarely dispensed through the e-pharmacy channel
although there is the emergence of e-pharmacy worldwide.
Request
For Discount - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=37127
Geographically, the global thrombolytic therapy
market is distributed over North America, Europe, Asia Pacific, Latin America,
and Middle East & Africa. North America holds the largest market share
globally, in terms of revenue, owing to high incidence of deep vein
thrombosis/pulmonary embolism (1.17 per 1,000 population per year), rise in
awareness, high diagnosis and treatment rate, and well-established health care
infrastructure. Europe is projected to account for the second largest market
share due to high diagnosis and treatment rate, considerable incidences of deep
vein thrombosis/pulmonary embolism, and presence of robust health care
facilities. Asia Pacific is expected to capture a significant market share
during the forecast period because of the presence of large patient pool,
particularly, in India and China. Latin America and Middle East & Africa
are silent contributors of the global thrombolytic therapy market.
Pre-book Thrombolytic Therapy
Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=37127<ype=S
Prominent players operating in the global market for
thrombolytic therapy include Eumedica, Genentech (a Roche Group Company),
Microbix, Boehringer Mannheim, SEDICO Pharmaceutical, Crinos, Livzon Zhuhai,
Medac, Mochida Pharmaceutical, Taj Pharmaceuticals Ltd., NDPharma, and
Syner-Medica.
More Trending
Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/key-players-in-depression-drugs-market-explore-novel-antidepressants-to-reduce-disease-burden-global-valuation-to-touch-mark-of-us-24-3-bn-tmr-301288569.html
https://www.prnewswire.com/news-releases/significant-rise-in-expenditures-to-improve-the-aesthetic-appeal-of-the-face-spells-growth-in-dermal-fillers-market-product-innovations-to-increase-the-longevity-of-effect-of-fillers-to-amplify-demand-tmr-301293803.html
https://www.prnewswire.com/news-releases/rising-incidence-of-sports-injuries-accidents-during-every-day-functioning-among-the-elderly-underscores-growth-in-adhesive-bandages-market-tmr-301298931.html
About Us
Transparency Market Research is a
next-generation market intelligence provider, offering fact-based solutions to
business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for
businesses to grow, evolve, and mature. Our real-time data collection methods
along with ability to track more than one million high growth niche products
are aligned with your aims. The detailed and proprietary statistical models
used by our analysts offer insights for making right decision in the shortest
span of time. For organizations that require specific but comprehensive
information we offer customized solutions through adhoc reports. These requests
are delivered with the perfect combination of right sense of fact-oriented
problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for
clients-specific problems with right methodology of research is the key to help
enterprises reach right decision.”
Contact
Transparency
Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel:
+1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
